公开(公告)号：US11649283B2

公开(公告)日：2023-05-16

申请号：US15488351

申请日：2017-04-14

申请人： ImmuNext, Inc ,  Janssen Pharmaceuticals, Inc.

发明人： Michael Molloy ,  Jay Rothstein ,  Dov Pechenick ,  Linda Snyder ,  Gordon Powers

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61P17/06 ,  A61P1/16 ,  A61P37/06 ,  A61P19/02 ,  A61P13/12 ,  A61P1/00 ,  A61K45/06 ,  A61K38/17 ,  A61K39/00

CPC分类号： C07K16/2803 ,  A61K38/17 ,  A61K39/395 ,  A61K39/3955 ,  A61K45/06 ,  A61P1/00 ,  A61P1/16 ,  A61P13/12 ,  A61P17/06 ,  A61P19/02 ,  A61P37/06 ,  C07K16/2827 ,  C07K16/2896 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92

摘要： The invention provides antagonistic and agonistic anti-human VISTA antibodies and antibody fragments. These antagonist antibodies and antibody fragments may be used to inhibit or block VISTA's suppressive effects on T cell immunity and thereby promote T cell immunity. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These antagonist antibodies and antibody fragments are especially useful in the treatment of cancer and infectious conditions. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.

公开(公告)号：US20230145356A1

公开(公告)日：2023-05-11

申请号：US17777769

申请日：2020-11-17

申请人： INXMED (NANJING) CO., LTD.

发明人： Zaiqi WANG ,  Jiangwei ZHANG ,  Jun JIANG

IPC分类号： A61K31/506 ,  A61K31/4439 ,  A61K31/5377 ,  A61P35/00 ,  A61K45/06 ,  A61P19/04 ,  A61P1/00 ,  A61P17/00

CPC分类号： A61K31/506 ,  A61K31/4439 ,  A61K31/5377 ,  A61P35/00 ,  A61K45/06 ,  A61P19/04 ,  A61P1/00 ,  A61P17/00

摘要： A use of a FAK inhibitor in the preparation of a drug for preventing and/or treating tumors having an NRAS mutation. A method for treating tumors that have experienced an NRAS mutation, which comprises administering an effective dose of a FAK inhibitor to an individual. A FAK inhibitor for treating tumors having an NRAS mutation. The FAK inhibitor is BI853520, defactinib, GSK2256098, PF-00562271, VS-4718 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230140818A1

公开(公告)日：2023-05-04

申请号：US16607035

申请日：2018-04-25

申请人： The University of Hong Kong

发明人： Ui Soon Khoo ,  Ho Frankie Tsoi ,  Chun Jade Gong ,  Kin Wah Terence Lee

IPC分类号： A61K31/55 ,  C12N15/113 ,  A61P35/00 ,  A61P1/00 ,  A61P15/08 ,  A61P1/16 ,  C07K16/28

摘要： Described are methods for treating cancers overexpressing hyperpolarization activated cyclic nucleotide-gated channel (HCN) isoforms HCN1, HCN2, HCN3, and/or HCN4. The cancers are treated by administering to a subject in need of treatment an effective amount of an HCN inhibitor. The HCN inhibitor can be an inhibitor of HCN1, HCN2, HCN3, or HCN4, or an inhibitor that inhibits any combination of HCN1, HCN2, HCN3, and HCN4. The described methods are useful for reducing tumor size, putting cancer in remission, and reducing or stopping proliferation of cancer stem cells.

公开(公告)号：US20230129095A1

公开(公告)日：2023-04-27

申请号：US17792594

申请日：2021-01-14

申请人： Protagonist Therapeutics, Inc.

发明人： Ashok BHANDARI ,  Brian Troy FREDERICK ,  Tran Trung TRAN ,  Gregory Thomas BOURNE

IPC分类号： C07K7/08 ,  A61P1/00

摘要： The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.

公开(公告)号：US11622988B2

公开(公告)日：2023-04-11

申请号：US17324130

申请日：2021-05-19

申请人： TCI CO., LTD.

发明人： Yung-Hsiang Lin

IPC分类号： A61K36/752 ,  A61K9/00 ,  A61P1/00 ,  A61K31/352

摘要： The present disclosure provides an extract of early-harvested Citrus reticulata fruit, and a method for reducing lipid accumulation by using the extract of early-harvested Citrus reticulata fruit. The extract of early-harvested Citrus reticulata fruit includes tetramethylisoscutellarein.

公开(公告)号：US20230094778A1

公开(公告)日：2023-03-30

申请号：US18047364

申请日：2022-10-18

申请人： EVOKE Pharma, Inc.

发明人： Marilyn R. CARLSON ,  Matthew J. D'ONOFRIO ,  David A. GONYER ,  Wayne ALVES

IPC分类号： A61K31/166 ,  A61P1/00 ,  A61K9/00 ,  A61K9/08 ,  A61K47/12

摘要： Metoclopramide is administered for the treatment of moderate to severe gastroparesis, in some embodiments, severe gastroparesis.

公开(公告)号：US20230089789A1

公开(公告)日：2023-03-23

申请号：US17908391

申请日：2021-03-01

申请人： CYCLOCHEM BIO CO., LTD.

发明人： Keiji TERAO ,  Keita CHIKAMOTO ,  Takahiro FURUNE ,  Ayumi NANRI ,  Yutaka YOSHIKAWA

IPC分类号： A61K31/724 ,  A61P1/14 ,  A61P1/00 ,  A23L33/125 ,  A23L33/00

摘要： An agent which can play a comparable or superior role to LS in improvement of intestinal tract function, enhancement of immune function, suppression of production of a putrefactive product, improvement of bowel movement or the like and an agent which can play a role in protection of the intestinal tract from a food emulsifier, a lipid peroxide or the like are provided. An intestinal tract function-improving agent, an immunoenhancing agent, a putrefactive product production-suppressing agent, a bowel movement-improving agent and an intestinal tract protection agent each containing a cyclodextrin as an active ingredient are provided. they can play a comparable or superior role to LS in improvement of intestinal tract function, enhancement of immune function, suppression of production of a putrefactive products, improvement of bowel movement or the like and the agent which can play a role in protection of the intestinal tract from a food emulsifier, a lipid peroxide or the like. Using the agents as an active ingredient, an anti-inflammatory agent, an immunostimulant, a body odor-improving agent, a stool odor-improving agent, a laxative, an intestinal tract protection agent and the like can also be provided.

公开(公告)号：US11602545B2

公开(公告)日：2023-03-14

申请号：US16770336

申请日：2018-11-30

申请人： Glycom A/S

发明人： Bruce McConnell ,  Louise Kristine Vigsnæs

IPC分类号： A61P25/06 ,  A61K31/702 ,  A61P1/00 ,  A61K35/20

摘要： The invention relates to a human milk oligosaccharide (HMO) for use in, a synthetic composition comprising an HMO for use in and a method for preventing or treating migraine in a human.

公开(公告)号：US20230060388A1

公开(公告)日：2023-03-02

申请号：US17811513

申请日：2022-07-08

申请人： SHANGHAI HENLIUS BIOTECH, INC.

发明人： Ming YANG ,  Wenfeng XU ,  Wei-dong JIANG ,  Jie XUE

IPC分类号： C07K16/28 ,  A61K47/68 ,  A61P1/00 ,  A61P35/00

摘要： Provided are anti-TIGIT antibodies that bind to “T cell immunoreceptor with Ig and ITIM domains (TIGIT)”, including multispecific anti-TIGIT antibodies with binding specificity for TIGIT and one or more additional antigen, and methods of using the same. The anti-TIGIT antibodies comprises a single domain antibody that binds to TIGIT. The one or more additional antigen comprises Programmed death protein 1 (PD1).

公开(公告)号：US20230055473A1

公开(公告)日：2023-02-23

申请号：US17944066

申请日：2022-09-13

申请人： HANGZHOU XINGAO BIOTECHNOLOGY CO., LTD.

发明人： Xiangshi TAN ,  Daofeng XIANG ,  Jianwu PEI

IPC分类号： A61K47/69 ,  A61K47/68 ,  A61P35/00 ,  A61P31/14 ,  A61P29/00 ,  A61P35/04 ,  A61P25/28 ,  A61P1/00 ,  A61P11/00 ,  A61P9/10

摘要： A natural immune agonist complex, consisting of an immune agonist and a targeted liposome, where the immune agonist is M(cGAMP)Ln. The targeted liposome is formed by a nanobody targeting a tumor microenvironment, a cell membrane-targeted penetrating peptide, or a blood-brain barrier-targeted penetrating peptide with a liposome through chemical bonding. This application further provides a preparation and application of the natural immune agonist complex.